NO20070912L - Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander - Google Patents

Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander

Info

Publication number
NO20070912L
NO20070912L NO20070912A NO20070912A NO20070912L NO 20070912 L NO20070912 L NO 20070912L NO 20070912 A NO20070912 A NO 20070912A NO 20070912 A NO20070912 A NO 20070912A NO 20070912 L NO20070912 L NO 20070912L
Authority
NO
Norway
Prior art keywords
treatment
conditions
nervous system
system disorders
procedure
Prior art date
Application number
NO20070912A
Other languages
English (en)
Norwegian (no)
Inventor
Darlene Coleman Deecher
Arthur Jay Cohn
Magid A Abou-Gharbia
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20070912L publication Critical patent/NO20070912L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20070912A 2004-07-22 2007-02-16 Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander NO20070912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59020304P 2004-07-22 2004-07-22
PCT/US2005/025974 WO2006012474A1 (en) 2004-07-22 2005-07-21 Method for treating nervous system disorders and conditions

Publications (1)

Publication Number Publication Date
NO20070912L true NO20070912L (no) 2007-04-20

Family

ID=35149631

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070912A NO20070912L (no) 2004-07-22 2007-02-16 Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander

Country Status (14)

Country Link
US (2) US20060020015A1 (https=)
EP (1) EP1773320A1 (https=)
JP (1) JP2008507550A (https=)
KR (1) KR20070034126A (https=)
CN (1) CN101410106A (https=)
AU (1) AU2005266994A1 (https=)
BR (1) BRPI0512186A (https=)
CA (1) CA2574310A1 (https=)
IL (1) IL180731A0 (https=)
MX (1) MX2007000853A (https=)
NO (1) NO20070912L (https=)
RU (1) RU2007102292A (https=)
WO (1) WO2006012474A1 (https=)
ZA (1) ZA200700578B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
CA2574315A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
AU2005266997A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
US8000005B2 (en) * 2006-03-31 2011-08-16 Prysm, Inc. Multilayered fluorescent screens for scanning beam display systems
JP2009502798A (ja) * 2005-07-21 2009-01-29 ワイス 神経系障害および状態の処置方法
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US9566264B2 (en) 2013-07-01 2017-02-14 Euthymics Bioscience, Inc. Combinations and methods

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3166571A (en) * 1962-06-06 1965-01-19 American Cyanamid Co 1-phenyl-1, 2-cyclopropane dicarboximides
US3344026A (en) * 1966-05-16 1967-09-26 American Cyanamid Co Dosage unit composition of 1-(p-chlorophenyl)-1, 2-cyclopropanedicarboximide for relief of depression
US3892772A (en) * 1973-12-04 1975-07-01 American Cyanamid Co Isomer of 1-(p-chlorophenyl)-1,2-cyclopropanedicarboximide and method of use
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US4131611A (en) * 1975-07-31 1978-12-26 American Cyanamid Company Azabicyclohexanes
US4118393A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Phenyl azabicyclohexanones
US4118417A (en) * 1977-06-23 1978-10-03 American Cyanamid Company Process for resolving cis-1-substituted phenyl-1,2-cyclopropanedicarboxylic acids
GR72713B (https=) * 1976-09-15 1983-12-01 American Cyanamid Co
US4435419A (en) * 1981-07-01 1984-03-06 American Cyanamid Company Method of treating depression using azabicyclohexanes
ATE37871T1 (de) * 1982-12-21 1988-10-15 Ciba Geigy Ag Substituierte azabicycloalkane, ihre verwendung, pharmazeutische praeparate, welche diese verbindungen enthalten, und verfahren zur herstellung dieser verbindungen.
US6204284B1 (en) * 1991-12-20 2001-03-20 American Cyanamid Company Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies
US6756388B1 (en) * 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
DE19919336A1 (de) * 1999-04-27 2000-11-16 Consortium Elektrochem Ind Verfahren zur Ringspaltung von Thiazolidinderivaten
US6372919B1 (en) * 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
EP1266659A1 (en) * 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal in combination with serotonin re-uptake inhibitor for the treatment of hot flushes
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
UA77234C2 (en) * 2001-12-05 2006-11-15 Wyeth Corp Monohydrate of venlafaxine hydrochloride and methods for its preparation (variants)
CN1630631A (zh) * 2001-12-05 2005-06-22 惠氏公司 新的文拉法星盐酸盐多晶型物及其制备方法
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
CA2574315A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions

Also Published As

Publication number Publication date
MX2007000853A (es) 2007-03-26
IL180731A0 (en) 2007-07-04
RU2007102292A (ru) 2008-08-27
AU2005266994A1 (en) 2006-02-02
CA2574310A1 (en) 2006-02-02
CN101410106A (zh) 2009-04-15
US20060020015A1 (en) 2006-01-26
EP1773320A1 (en) 2007-04-18
JP2008507550A (ja) 2008-03-13
KR20070034126A (ko) 2007-03-27
US20120010260A1 (en) 2012-01-12
BRPI0512186A (pt) 2008-02-19
ZA200700578B (en) 2010-06-30
WO2006012474A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
NO20070912L (no) Fremgangsmate for behandling av nervesystemforstyrrelser og tilstander
NO20070915L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
TNSN07027A1 (en) Pyrrolo-pyridine kinase modulators
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2005103041A3 (en) Treatment of cns disorders using cns target modulators
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
CY1109760T1 (el) Παραγωγα ινδολης-3-θειου
TW200407305A (en) Novel compounds
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
TW200510303A (en) Novel compounds
NO20072887L (no) Forbindelser og sammensetninger som protein kinase inhibitorer
NO20070908L (no) Sammensmeltede ringheterocykelkinasemodulatorer
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
EA200601074A1 (ru) Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли)
DE69703617D1 (de) Verwendung von optisch reines (+) norcisapride zur behandlung von erbrechen und zns-störungen
WO2023077127A3 (en) Psychoplastogenic n-substituted indoles
NO20065768L (no) Karbonsamid-opioidforbindelser
SI1585510T1 (sl) Alfa-aminoamidni derivati, koristni kot sredstva proti migreni
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
NO20065297L (no) Anvendelse av GPCR54 ligander til behandling av infertilitet
DE602004009211D1 (de) Indazol-3-one und analoga und derivate davon, die die funktion des vanilloid-1-rezeptors (vr1) modulieren
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
WO2007013936A3 (en) Method for treating nervous system disorders and conditions